Literature DB >> 25900362

The catalytic function of renalase: A decade of phantoms.

Graham R Moran1.   

Abstract

Ten years after the initial identification of human renalase the first genuinely catalytic substrates have been identified. Throughout the prior decade a consensus belief that renalase is produced predominantly by the kidney and catalytically oxidizes catecholamines in order to lower blood pressure and slow the heart has prevailed. This belief was, however, based on fundamentally flawed scientific observations that did not include control reactions to account for the well-known autoxidation of catecholamines in oxygenated solutions. Nonetheless, the initial claims have served as the kernel for a rapidly expanding body of research largely predicated on the belief that catecholamines are substrates for this enzyme. The proliferation of scientific studies pertaining to renalase as a hormone has proceeded unabated despite well-reasoned expressions of dissent that have indicated the deficiencies of the initial observations and other inconsistencies. Our group has very recently identified isomeric forms of β-NAD(P)H as substrates for renalase. These substrates arise from non-specific reduction of β-NAD(P)(+) that forms β-4-dihydroNAD(P) (β-NAD(P)H), β-2-dihydroNAD(P) and β-6-dihydroNAD(P); the latter two being substrates for renalase. Renalase oxidizes these substrates with rate constants that are up to 10(4)-fold faster than any claimed for catecholamines. The electrons harvested are delivered to dioxygen via the enzyme's FAD cofactor forming both H2O2 and β-NAD(P)(+) as products. It would appear that the metabolic purpose of this chemistry is to alleviate the inhibitory effect of β-2-dihydroNAD(P) and β-6-dihydroNAD(P) on primary metabolism dehydrogenase enzymes. The identification of this genuinely catalytic activity for renalase calls for re-evaluation of much of the research of this enzyme, in which definitive links between renalase catecholamine consumption and physiological responses were reported. This article is part of a Special Issue entitled: Physiological enzymology and protein functions.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Catecholamine; FAD; Flavin; NAD; Oxidase; Renalase

Mesh:

Substances:

Year:  2015        PMID: 25900362     DOI: 10.1016/j.bbapap.2015.04.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Renalase as a Novel Biomarker for Evaluating the Severity of Hepatic Ischemia-Reperfusion Injury.

Authors:  Huili Li; Jianrong Guo; Hongli Liu; Yanfeng Niu; Lixia Wang; Kun Huang; Jiliang Wang
Journal:  Oxid Med Cell Longev       Date:  2016-10-27       Impact factor: 6.543

Review 2.  Extracellular renalase protects cells and organs by outside-in signalling.

Authors:  Yang Wang; Robert Safirstein; Heino Velazquez; Xiao-Jia Guo; Lindsay Hollander; John Chang; Tian-Min Chen; Jian-Jun Mu; Gary V Desir
Journal:  J Cell Mol Med       Date:  2017-02-26       Impact factor: 5.310

3.  Relationship between microRNA-146a expression and plasma renalase levels in hemodialyzed patients.

Authors:  Marcin Dziedzic; Tomasz Powrózek; Ewelina Orłowska; Wojciech Koch; Wirginia Kukula-Koch; Kinga Gaweł; Anna Bednarek-Skublewska; Teresa Małecka-Massalska; Janusz Milanowski; Beata Petkowicz; Janusz Solski
Journal:  PLoS One       Date:  2017-06-14       Impact factor: 3.240

4.  Functional polymorphism of the renalase gene is associated with cardiac hypertrophy in female patients with aortic stenosis.

Authors:  Ewa Orlowska-Baranowska; Lucja Gadomska Vel Betka; Jaroslaw Gora; Rafal Baranowski; Ewa Pedzich-Placha; Dariusz Zakrzewski; Angelika Dlugosz; Helena Kossowska; Agnieszka Zebrowska; Ewelina Zakoscielna; Anna Janiszewska; Tomasz Hryniewiecki; Zbigniew Gaciong; Grzegorz Placha
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

5.  Improved soluble expression and use of recombinant human renalase.

Authors:  Clifford S Morrison; Elena E Paskaleva; Marvin A Rios; Thomas R Beusse; Elaina M Blair; Lucy Q Lin; James R Hu; Aidan H Gorby; David R Dodds; William B Armiger; Jonathan S Dordick; Mattheos A G Koffas
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

6.  Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes.

Authors:  Erica P Cai; Yuki Ishikawa; Wei Zhang; Nayara C Leite; Jian Li; Shurong Hou; Badr Kiaf; Jennifer Hollister-Lock; Nese Kurt Yilmaz; Celia A Schiffer; Douglas A Melton; Stephan Kissler; Peng Yi
Journal:  Nat Metab       Date:  2020-07-27

7.  Elevated Levels of Renalase, the β-NAD(P)H Isomerase, Can Be Used as Risk Factors of Major Adverse Cardiovascular Events and All-Cause Death in Patients with Chronic Kidney Disease.

Authors:  Wojciech Knop; Natalia Maria Serwin; Elżbieta Cecerska-Heryć; Bartłomiej Grygorcewicz; Barbara Dołęgowska; Aleksandra Gomółka; Magda Wiśniewska; Kazimierz Ciechanowski
Journal:  Biomolecules       Date:  2021-10-14

Review 8.  Renalase: a novel regulator of cardiometabolic and renal diseases.

Authors:  Anupama Vijayakumar; Nitish R Mahapatra
Journal:  Hypertens Res       Date:  2022-08-08       Impact factor: 5.528

9.  Sex-related differences in human plasma NAD+/NADH levels depend on age.

Authors:  Luisa Schwarzmann; Rainer Ullrich Pliquett; Andreas Simm; Babett Bartling
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.